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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2014, ElsevierBackground: Carotid angioplasty and stent (CAS) placement has emerged as an attractive
revascularization strategy for patients with internal carotid artery stenosis. However, the
effectiveness and safety of CAS were not fully evaluated, mainly because of methodological
difficulties in finding an appropriate comparison group.
Methods: Patients who underwent CAS were identified from Taiwan’s National Health Insur-
ance claims database between 2005 and 2008. The incidence rate of ischemic stroke after
CAS was compared with that of the year prior to the procedure using a self-controlled case se-
ries analysis and a conditional Poisson regression model. Logistic regression was conducted to
identify factors associated with poor outcome.
Results: A total of 1258 patients who had undergone CAS were included, and 73 cases (5.8%) of
death or ischemic stroke occurred during the index hospitalization. Within 1 year after CAS, 74
patients died and 80 experienced an ischemic stroke. Of the 1184 patients who were followed
for 360 days, the rate ratio for ischemic stroke decreased to 0.21 (95% CI: 0.08e0.51) between
31 and 180 days, and 0.10 (95% CI: 0.03e0.32) between 181 and 360 days. Statin therapy was
associated with a reduced risk of death or ischemic stroke in the 1st month (odds ratio of 0.53;
95% CI: 0.32e0.90). Conversely, the use of nonsteroidal anti-inflammatory agents, possibly
histamine-2 receptor blockers, and CAS performed by low-volume operators were associated
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Carotid stent and stroke 275Conclusion: CAS reduced the long-term risk for ischemic stroke. Self-controlled case series
analysis might be an appropriate design for evaluating device safety and effectiveness.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Extracranial internal carotid artery stenosis is an important
cause of ischemic stroke. Carotid endarterectomy (CEA)
and carotid stenting (CAS) are the two major treatment
strategies for extracranial carotid revascularization. The
results from the North American Symptomatic Carotid
Endarterectomy Trial and the European Carotid Surgery
Trial have demonstrated that, in symptomatic patients with
high-grade (70e99%) internal carotid artery (ICA) stenosis,
CEA is highly beneficial for patients with recent transient
ischemic attacks (TIA) and nondisabling strokes; and the
role of CEA is less certain in symptomatic patients with mild
(<50%) to moderate (50e69%) stenosis, as well as asymp-
tomatic patients.1e3 CAS, however, has emerged as a po-
tential alternative treatment for patients with carotid
artery disease who are at high risk for CEA.4 In the Study of
Angioplasty with Protection in Patients at High Risk for
Endarterectomy Trial, which included both symptomatic
and asymptomatic patients (i.e., close to 70% asymptom-
atic) with ICA stenosis and a high risk for CEA, it was found
that CAS with the use of an emboli-protection device was
not inferior to CEA in patients with severe ICA stenosis and
coexisting conditions.5 Additionally, there were no signifi-
cant differences in the 3-year outcome (i.e., stroke,
myocardial infarction, or death) between the CEA and CAS
groups.6
However, due to relatively limited evidence on the
effectiveness and safety of CAS, the widespread use of CAS
should not be uniformly justified in patients with various
cerebrovascular risks.7,8 Some reports demonstrate that
CAS resulted in a higher risk of stroke, myocardial infarc-
tion, and death.9 Also, little is known about whether or not
CAS provides additional clinical benefits over optimal
medical treatment. Although the current guidelines in
Taiwan recommend that CAS is only considered for patients
with symptomatic stenosis of >60% or asymptomatic ste-
nosis of >80% with certain conditions (i.e., patients who
are unable to receive CEA, who previously received radio-
therapy, and who have tandem stenosis in the carotid ar-
tery),10 in recent years, a rapidly increasing number of
patients underwent CAS, and CEA has become a rare
practice in Taiwan.11e13
The effectiveness and safety of CAS in the treatment of
internal carotid artery stenosis in real clinical settings were
not fully evaluated, mainly because of methodological
difficulties. Patients undergoing CAS may differ substan-
tially from those who did not in terms of the anatomic
characteristics of the carotid artery (e.g., focal stenosis or
long segment occlusion), clinical presentations, and func-
tional status. Therefore, it is difficult to identify a suitable
comparison group of untreated patients or a comparable
group that received CEA with similar baseline risks. In thissetting, a self-controlled case-series design may be appro-
priate to overcome the issue of no appropriate comparison
group.14 The objective of this study was to evaluate the
efficacy, safety, and risk factors associated with poor
outcome in patients with significant ICA stenosis receiving
CAS, using a nationwide, self-controlled case-series
analysis.
Materials and methods
Patients and participants
Taiwan’s National Health Insurance (NHI) claims database
includes complete outpatient visits, hospital admissions,
prescriptions and procedures, disease, and vital status for
99% of the 23 million people in Taiwan. We determined the
longitudinal medical history of each beneficiary by linking
several computerized claims data sets and the National
Death Registry using the civil identification number unique
to each beneficiary and date of birth.
The patients who underwent CAS placement between 1
January 2005 and 31 December 2008 were identified via
services or procedure claims in the inpatient data set. The
date of hospitalization was defined as the index date. A total
of nine different types of stents were approved for treating
carotid artery stenosis in Taiwan during the study period
(Table S1). For those who had received two or more CAS
procedures, the date of the first hospitalization was defined
as the index date. Exclusion criteria were as follows: (1)
patients who underwent CAS in 2004; (2) had missing infor-
mation on sex; (3) were previously admitted to a hospital or
outpatient clinic under the diagnosis code of atrial fibrilla-
tion and flutter (i.e., International Classification of Diseases,
9th Revision, Clinical Modification [ICD-9-CM] code of 427.3)
and cancer (code 140-239); or (4) did not have continuous
insurance coverage 12 months before the index date. The
protocol of this study was approved by the National Taiwan
University Hospital Research Ethics Committee.
Outcome definition
The outcome of interest was death or major ischemic
stroke leading to hospitalization, which was defined by the
following criteria: (1) a hospital discharge diagnosis code of
433, 434, and 436 from the inpatient data set; (2) a record
of receiving a computed tomography or magnetic resonance
imaging of the brain; (3) hospitalization for 7 days or
longer; (4) obtaining a certificate for stroke; and (5) a re-
cord of rehabilitation, consultation, or therapy during
hospitalization. A previous validation study using a hospital
chart review reported a high accuracy of 98% using this
definition.15
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Inpatient and outpatient diagnoses files, as well as the
prescription files, during the 12-month period before the
index date were used to ascertain the patients’ history of
underlying disease (ICD-9-CM codes are provided in Table
S2) and concomitant drug use, including antiplatelet
agents, cardiovascular-related medications, lipid-lowering
agents, insulins and antidiabetic agents, cyclooxygenase-2
selective, and nonselective nonsteroidal anti-
inflammatory agents (NSAIDs) (Table S3). We also
collected information on the operating physicians (i.e.,
age, sex, operator volume). Operator volume was defined
as the total number of CAS procedures performed by the
physician 1 year before the index date.
Statistical analysis
For each individual, the observation period started from
360 days before the index date and ended in death or
360 days after the index date. The numbers of deaths or
periprocedural ischemic strokes occurring in the index
hospitalization were reported.
Risk factors, including age, comorbidities, concomitant
medication use, and healthcare providers’ characteristics,
that were possibly associated with: (1) death or ischemic
stroke; and (2) ischemic stroke in the first 30 days after
index hospitalization, were examined by calculating odds
ratios (ORs) and 95% confidence intervals (CIs) using the
logistic regression model.
To evaluate effectiveness, we examined death or
ischemic stroke occurrence after index hospitalization, and
the remaining follow-up time for each CAS recipient was
further classified according to the following time periods:
1e30 days, 31e180 days, and 181e360 days after the index
hospitalization. The rate of ischemic stroke in Days 1e360
before the index date was used as the baseline reference.
Rate ratios (RRs) and 95% CIs for: (1) death or ischemic
stroke; and (2) ischemic stroke in each postprocedural
period were determined via conditional Poisson regression
analyses.
Furthermore, a stratified analysis was performed to
evaluate potential effect modification. CAS recipients were
classified according to the following characteristics: (1) age
70 years and <70 years; (2) sex; (3) diabetes; (4) ischemic
stroke 1 year prior to CAS; (5) ischemic heart disease; (6)
chronic renal disease; (7) use of statin(s); (8) underwent
CAS in 2005e2006 or 2007e2008; and (9) healthcare pro-
vider with high or low operator volume. The likelihood ratio
test was used to compare the full model with the interac-
tion terms against the model without the interaction terms
and test whether the risk is modified by these character-
istics. A two-sided p value <0.05 was considered to be
statistically significant.
Results
We identified 1487 patients, aged 20 years or older, who
had undergone an extracranial CAS between 2005 and
2008. After excluding those who did not meet our study
entry criteria, a total of 1258 first-time CAS recipientswithout prior diagnoses of atrial fibrillation/flutter or
cancer were included in the final analysis (Fig. 1). Among
them, the mean age was 71.2 years and 80% were men.
The patient characteristics, including comorbidities
and concomitant drug use at CAS placement, are pre-
sented in Table 1. Approximately 80% of patients had hy-
pertension, 37% had diabetes, and 64% had a prior history
of ischemic stroke. Nearly all of the patients received
antiplatelet or anticoagulants therapy, but only one third
were treated with a statin. A comparison of recipients’
characteristics revealed that a higher proportion of pa-
tients received statin therapy, whereas a lower proportion
of patients were on aspirin therapy in 2007e2008 than in
2005e2006.Safety
Within the 1st year after CAS, 74 patients died and an
additional 80 patients presented with an ischemic stroke.
Among them, four deaths and 69 ischemic strokes (i.e.,
5.8% of the study patients) occurred in the index
hospitalization.
When examining the risk factors associated with death
or ischemic stroke 0e30 days after CAS placement, we
found that statin therapy was significantly associated with a
reduced risk with an odds ratio of 0.53 (95% CI: 0.32e0.90).
Conversely, the use of nonselective NSAIDs and possibly
histamine-2 receptor blockers were associated with a
higher risk (OR: 2.30, 95% CI: 1.39e3.80 and OR: 2.41, 95%
CI: 0.99e5.91, respectively). Meanwhile, CAS performed by
low-volume operators (OR: 2.32; 95% CI: 1.05e5.09) was
also associated with poor outcomes. The findings were
similar when examining the risk for ischemic stroke,
although some of the estimates were not statistically sig-
nificant due to a fewer number of events (Table 2).Effectiveness
Table 3 summarizes the rate ratios for death or ischemic
stroke during different risk periods after extracranial CAS.
The rate ratio for death or ischemic stroke was significantly
elevated on Days 1e30 after the index hospitalization (RR:
4.11; 95% CI: 2.51e6.74); however, thereafter, it decreased
close to 1.0. When the analysis was restricted to the 1184
patients who survived at least 360 days after the proce-
dure, there was a significant decrease in the risk for
ischemic stroke during the period of 31e180 days (RR: 0.21;
95% CI: 0.08e0.51) and 181e360 days (RR: 0.10; 95% CI:
0.03e0.32) after index hospitalization.
To determine whether the efficacy of CAS placement
varied among different subgroups, we conducted analyses
stratified according to the patients’ and healthcare pro-
viders’ characteristics (Table 4). Although there was no
significant effect modification, there appeared to be an
excessive number of ischemic strokes occurring 1e30 days
after index hospitalization for female patients without
ischemic stroke 1 year prior to CAS, and those receiving CAS
in 2007e2008. Moreover, statin users had a consistently
lower rate of ischemic stroke throughout the year after CAS
placement.
Figure 1 Study flow.
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The findings of the present study demonstrate that CAS
reduces the risk of ischemic stroke in a time-dependent
fashion. The risk reduction began to appear in the 1st month
after CAS, and its protective effects were augmented
thereafter until the end of the 1st year. The incidence rate
of the composite endpoint of death or stroke was higher in
the first 30 days, but declined in the following months.
The strength of this study was that the case-series
design eliminated the influence of risk factors for stroke
that were not recorded in the claims database (e.g., blood
pressure, serum lipid concentrations, body mass index,
cigarette smoking, and alcohol consumption). Additionally,
the stable confounders that could not be measured, were
poorly measured, or were unknown, canceled each other
out.16 Furthermore, as the harm/benefit profile of CAS
after the procedure is expected to change over time, risks
in each predefined time period can be explicitly estimated
by using the case series design.17In the present study, only 5% of the patients had expe-
rienced ischemic stroke in the year prior to CAS. A few
perioperative or early postoperative adverse events may
outweigh the benefits. Therefore, routine CAS for asymp-
tomatic and even symptomatic carotid stenosis is now
regarded as inappropriate.18 A judicious decision should be
made after considering the trade-offs between baseline
risk, perioperative complications, and long-term beneficial
effects after CAS.18
The American Heart Association/American Stroke Asso-
ciation (AHA/ASA) guidelines suggest that CAS is reasonable
when performed by operators with established periproce-
dural stroke/death rate of 4e6%.3 The immediate compli-
cation rate in this nationwide case series was comparable
to that threshold, and may account for the learning curve
of physicians for adapting to the new invasive technique in
Taiwan.19,20 A recent observational study showed that a
lower annual operator volume and early experience are
associated with increased 30-day mortality among older
patients undergoing CAS.21 In this case series, more than
Table 1 Baseline patient demographics, comorbidities, medication use, and hospital and physician characteristics in patients
receiving extracranial carotid artery stenting between 2005 and 2008.
Total (n Z 1258) 2005e2006 (n Z 563) 2007e2008 (n Z 695)
Patient characteristics
Age (mean  SD) 71.2  10.1 71.3  10.3 71.1  10.0
Male 80.9 79.8 81.9
Comorbidities (%)
Diabetes mellitus 36.9 35.7 37.8
Hypertension 80.8 79.6 81.9
Ischemic heart disease 43.5 42.1 44.6
Myocardial infarction 3.1 3.0 3.2
Congestive heart failure 8.6 7.8 9.2
Ischemic stroke 64.0 62.9 64.9
Chronic renal disease 5.5 4.6 6.2
Chronic liver disease 6.3 5.7 6.8
Chronic lung disease 21.8 21.1 22.3
Peptic ulcer disease 20.9 21.0 20.9
Osteoarthritis 23.9 23.1 24.6
Rheumatoid arthritis 1.7 1.8 1.6
Medication use (%)
Aspirin 60.3 62.9 58.1
Clopidogrel 33.9 35.5 32.7
Warfarin 3.3 4.6 2.3
Angiotensin converting enzyme inhibitors/
angiotensin receptor blockers
48.2 50.1 46.6
Beta-blockers 32.9 32.7 33.1
Calcium channel blockers 43.4 46.2 41.2
Diuretics 16.9 21.9 13.0
Other antihypertensive agents 9.9 11.6 8.5
Insulins 3.3 3.6 3.0
Metformin 18.7 16.7 20.3
Sulfonylureas 21.8 20.3 23.0
Glinides 2.7 4.3 1.4
Thiazolidinediones 4.7 5.2 4.3
Statins 32.8 30.9 34.4
Fibrates 3.7 3.9 3.5
COX-2 selective NSAIDs 1.8 1.8 1.9
Nonselective NSAIDs 14.1 13.1 14.8
Proton pump inhibitors 3.89 3.91 3.88
Histamine-2 receptor blockers 3.18 2.49 3.74
Physician characteristics (%)
Age (mean  SD) 44.1  7.1 43.6  6.7 44.5  7.4
Male 91.8 93.4 90.8
Low-volume operatorsa 84.1 82.1 85.8
NSAIDs Z nonsteroidal anti-inflammatory agents.
Mean procedural volume for a hospital: 40.28 procedures per year.
a Mean operator volume: 15.16 procedures per year.
278 C.-H. Chang et al.half of the procedures were performed by low-volume op-
erators, and this was associated with a 2.3-fold risk for peri-
and early postoperative death or ischemic stroke. Our
findings, in general, support the challenges of ensuring
adequate expertise among operators and suggest collecting
more quality data regarding operators’ performances dur-
ing the early dissemination of new procedures, such as
carotid stenting, to optimize outcomes.22,23
A previous study demonstrated that statin use was the
only independent protective factor to reduce perioperative
morbidity with carotid stenting.24 Statins are underused inTaiwan, and the attainment rate of low-density lipoprotein
cholesterol levels is the lowest among all the Asian coun-
tries.25,26 In this analysis, we demonstrated that statin use
was associated with a 50% risk reduction for peri- and
postoperative death or ischemic stroke, but only one third
of patients with documented significant carotid stenosis
received statin therapy before CAS. As statins are much
more cost-effective than CAS for the secondary prevention
of ischemic stroke,27,28 a strategy which prioritizes phar-
maceutical therapy rather than invasive intervention
should be reconsidered. Conversely, NSAIDs and possibly
Table 2 Risk factors for death or ischemic stroke 0e30 days after extracranial carotid artery stenting.
Death or ischemic strokea Ischemic strokeb
No. of events Odds ratio (95% CI) No. of events Odds ratio (95% CI)
Patient characteristics
Age 70 y 53 0.95 (0.61e1.47) 41 0.93 (0.57e1.52)
Male 72 1.00 (0.58e1.73) 59 1.25 (0.64e2.41)
Comorbidities
Diabetes mellitus 32 0.96 (0.61e1.50) 28 1.17 (0.71e1.91)
Hypertension 72 1.01 (0.58e1.75) 59 1.28 (0.66e2.48)
Ischemic heart disease 35 0.83 (0.54e1.29) 31 1.05 (0.64e1.70)
Myocardial infarction <5 1.99 (0.76e5.21) <5 2.12 (0.73e6.18)
Congestive heart failure 10 1.38 (0.69e2.76) 9 1.64 (0.79e3.41)
Ischemic stroke 52 0.78 (0.50e1.21) 43 0.89 (0.54e1.47)
Chronic renal disease 8 1.79 (0.83e3.88) 7 2.06 (0.90e4.70)
Chronic liver disease 9 1.77 (0.85e3.67) 8 2.08 (0.96e4.53)
Chronic lung disease 21 1.12 (0.67e1.86) 19 1.41 (0.82e2.43)
Peptic ulcer disease 21 1.18 (0.71e1.97) 19 1.49 (0.86e2.57)
Medication use
Metformin 18 1.11 (0.65e1.90) 16 1.28 (0.72e2.29)
Thiazolidinediones <5 0.69 (0.21e2.26) <5 0.59 (0.14e2.47)
Statins 19 0.53 (0.32e0.90) 17 0.62 (0.36e1.09)
Nonselective NSAIDs 23 2.30 (1.39e3.80) 20 2.65 (1.54e4.58)
Histamine-2 receptor blockers 6 2.41 (0.99e5.91) <5 2.60 (0.98e6.90)
Physician characteristics
Low-volume operators 82 2.32 (1.05e5.09) 64 2.08 (0.89e4.88)
NSAIDs Z nonsteroidal anti-inflammatory agents.
a Total number of patients included in the analysis (nZ 1258), model adjusted by hospital characteristics (medical centers, private vs.
public hospitals, and hospital procedural volume).
b Includes patients who were followed up for 360 days after carotid stenting (n Z 1184).
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ischemic stroke in the first 30 days after CAS. However, the
reasons behind the associations need further clarification.
There are still several limitations in this study. Cere-
brovascular symptoms, carotid echo and angiographic data,
blood tests (including lipid and glucose profile), brain im-
aging, and technical information were not recorded in
Taiwan’s NHI claims database. The baseline characteristics
of patients and the indications of CAS were heterogeneous,
therefore therapeutic responses might not be predictable.Table 3 Rate ratioa and 95% confidence intervals for death or is
carotid artery stenting.
1e360 d before
index hospitalization
1e30 d after i
hospitalization
Death or ischemic strokeb
Number of events 62 21
Rate ratio Reference 4.11 (2.51e6.7
Ischemic strokec
Number of events 59 NA
Rate ratio Reference 0.82 (0.30e2.2
NA Z not available as the number is < 5.
a Conditional Poisson regression with 1e360 days before carotid art
b Total number of patients included in the analysis (n Z 1258).
c Includes patients who were followed up for 360 days after carotidFor example, bifurcation lesions may have different mani-
festations and responses to CAS, but this information was
not available.29 In addition, the effects of anatomical and
technical factors associated with stroke or death could not
be evaluated. Some operators used proximal or distal filter
protection devices during CAS.30,31 As patients paid for the
novel devices themselves, the effects of these devices in
reducing perioperative ischemic stroke were unknown. As a
result of information regarding the type of stroke (i.e.,
ipsilateral or contralateral) not being available in thechemic stroke during different risk periods after extracranial
Risk periods
ndex 31e180 d after index
hospitalization
181e360 d after index
hospitalization
35 32
4) 1.06 (0.91e2.07) 1.02 (0.66e1.56)
12 NA
6) 0.21 (0.08e0.51) 0.10 (0.03e0.32)
ery stenting as a reference.
stenting (n Z 1184).
Table 4 Rate ratio for ischemic stroke during different risk periods among subgroups of patients after extracranial carotid
artery stenting.
Patient subgroups Risk periods
1e360 d
before index
hospitalization
1e30 d after index
hospitalization
31e180 d after
carotid artery
stenting
181e360 d after
carotid artery
stenting
Age 70 y 1 0.93 (0.22e3.93) 0.47 (0.18e1.22) 0.23 (0.07e0.75)
Age <70 y 1 0.74 (0.18e3.06) NA NA
Male 1 0.47 (0.11e1.92) 0.23 (0.09e0.58) 0.11 (0.04e0.36)
Female 1 3.47 (0.72e16.69) NA NA
Patients with diabetes 1 0.97 (0.23e4.10) 0.19 (0.05e0.82) NA
Patient without diabetes 1 0.71 (0.17e2.97) 0.21 (0.07e0.70) 0.17 (0.05e0.57)
Patients with ischemic stroke
1 y prior to stenting
1 0.56 (0.14e2.33) 0.17 (0.05e0.55) 0.05 (0.01e0.33)
Patients without ischemic
stroke 1 y prior to stenting
1 1.52 (0.35e6.60) 0.30 (0.07e1.32) 0.25 (0.06e1.07)
Patients with ischemic heart disease 1 0.97 (0.23e4.10) 0.29 (0.09e0.96) NA
Patients without ischemic heart disease 1 0.71 (0.17e2.97) 0.14 (0.03e0.59) 0.17 (0.05e0.57)
Patients with chronic renal disease 1 NA NA NA
Patients without chronic renal disease 1 0.85 (0.31e2.35) 0.21 (0.09e0.53) 0.10 (0.03e0.33)
Statin users 1 0.90 (0.03e0.33) 0.18 (0.04e0.76) 0.07 (0.01e0.54)
Statin nonusers 1 0.76 (0.18e3.16) 0.23 (0.07e0.74) 0.12 (0.03e0.51)
Patients who received stenting in 2005e2006 1 NA 0.21 (0.05e0.90) 0.09 (0.01e0.63)
Patients who received stenting in 2007e2008 1 1.35 (0.48e3.79) 0.20 (0.06e0.66) 0.11 (0.03e0.45)
High-volume operators 1 1.10 (0.14e8.54) NA 0.18 (0.02e1.39)
Low-volume operators 1 0.76 (0.24e2.43) 0.25 (0.10e0.63) 0.08 (0.02e0.34)
NA Z not estimable, as no/few events occurred during the risk period in the patient subgroup.
280 C.-H. Chang et al.claims database, we could only evaluate the overall safety
and efficacy of CAS. Lastly, we only included patients who
received CAS under the NHI reimbursement criteria.
Therefore, we cannot generalize our results to other
revascularization strategies, such as CEA or a combined
therapy of CAS followed by CEA.
In conclusion, CAS appears to reduce the risk of ischemic
stroke 1 month after the procedure, with increasing pro-
tection in the following months. However, the beneficial
effects are only substantiated when the risk reduction ex-
ceeds the perioperative and early postoperative complica-
tions, which could be attributed to baseline patient
characteristics, adequacy of pharmaceutical management
for atherosclerosis, and operator experiences. Further
studies which focus on improving the safety profiles and
maximizing the long-term effectiveness of CAS are
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